Showing 1 - 6 results of 6 for search 'Morris TW', query time: 0.03s Refine Results
  1. 1
    Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones

    Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones by Haas W, Sanfilippo CM, Hesje CK, Morris TW

    Published 2013-05-01
    Get full text
    Article
  2. 2
    Clinical outcomes with besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis due to potentially consequential pathogens

    Clinical outcomes with besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis due to potentially consequential pathogens by Comstock TL, Morris TW, Gearinger LS, DeCory HH

    Published 2014-04-01
    Get full text
    Article
  3. 3
    Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections

    Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections by Silverstein BE, Morris TW, Gearinger LS, DeCory HH, Comstock TL

    Published 2012-11-01
    Get full text
    Article
  4. 4
    Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile

    Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility prof... by Haas W, Gearinger LS, Usner DW, DeCory HH, Morris TW

    Published 2011-09-01
    Get full text
    Article
  5. 5
    Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes

    Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes by Morris TW, Gearinger LS, Usner DW, Paterno MR, DeCory HH, Comstock TL, Haas W

    Published 2011-09-01
    Get full text
    Article
  6. 6
    Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery

    Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery by Bucci FA Jr, Evans RE, Amico LM, Morris TW, Fluet AT, Sanfilippo CM, DeCory HH, Comstock TL

    Published 2015-05-01
    Get full text
    Article

Search Tools: